Walgreens Launches 2024-2025 Flu Index to Track Weekly Flu ActivityÂ
The online tool provides weekly updates on flu activity across states and cities, highlighting regions with the highest increases and historical trends.
The online tool provides weekly updates on flu activity across states and cities, highlighting regions with the highest increases and historical trends.
The online tool provides weekly updates on flu activity across states and cities, highlighting regions with the highest increases and historical trends.
Read MorePneumonia is a potentially life-threatening infection of the lungs that inflames alveoli and spurs the overproduction of purulent material. Typically afflicting neonates and seniors, the COVID pandemic has revealed the importance of proper pneumonia care for all patients.Â
Read MoreTopline results demonstrated that the drug was well-tolerated over a 10-day period and achieved consistent plasma levels without the need for ritonavir co-administration.Â
Read MoreFuture updates to COVID-19 treatment recommendations will transition to professional medical societies.
Read MoreA new case report sheds light on the first documented transmission of bird flu from cow to human.
Read MoreUH15-38 shows potential in preventing lung injury and reducing inflammation in severe influenza when administered even five days after infection.
Read MoreResearchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read MoreIn this 2023 update of RT’s pharmacological treatment of respiratory disorders, the most commonly administered classes of pulmonary medications are reviewed.
Read MorePfizer’s Paxlovid is the fourth drug—and first oral antiviral pill—approved by the FDA to treat COVID-19 in adults.
Read MoreResearchers identified potential broad-spectrum antiviral agents that can target multiple families of RNA viruses that pose a significant threat for future pandemics.
Read MoreThe oral, direct-acting antiviral drug candidate is being evaluated in the global phase 3 SUNRISE-3 registrational trial for the treatment of COVID-19 in outpatients at high risk for disease progression regardless of vaccination status.
Read MoreEDP-323 is supported by in vitro data demonstrating a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B.
Read MoreThe drug recently received emergency regulatory approval from the Ministry of Health, Labour, and Welfare of Japan for the treatment of SARS-CoV-2 infection.
Read MoreA multisite clinical trial will evaluate an investigational COVID-19 antiviral known as the Shionogi antiviral (S-217622) or ensitrelvir fumaric acid.
Read MoreA survey found individuals with COPD were overwhelmingly positive about the prospect of taking an antiviral nasal spray throughout the winter season to prevent COPD flare-ups.
Read MoreENA Respiratory and the COPD Foundation are partnering to develop an antiviral nasal spray to prevent and reduce incidence and severity of respiratory viral infections in people with chronic lung diseases like COPD.
Read MoreThe US FDA has authorized the emergency use of Paxlovid (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients age 12 and older.
Read MoreAccording to data, Pfizer’s COVID-19 antiviral Paxlovid reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) with no patient deaths.
Read MorePfizer says its antiviral pill Paxlovid reduced the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19.
Read MoreMerck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Read MoreMerck’s COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50% compared to placebo.
Read MoreThe US government will procure approximately 1.7 million courses of an investigational COVID-19 antiviral molnupiravir (MK-4482) from Merck, pending EUA or approval from the FDA.
Read MoreThe experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.
Read MoreThe FDA is alerting healthcare professionals and compounders of potential risks associated with compounding remdesivir drug products.
Read More